GC
IRWD icon

Grimes & Company’s Ironwood Pharmaceuticals IRWD Stock Holding History

Grimes & Company’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Buy
34,806
+8,919
+34% +$34.4K ﹤0.01% 441
2026
Q1 		$90.9K Hold
25,887
– – ﹤0.01% 427
2025
Q4 		$87.2K Sell
25,887
-15,107
-37% -$39.2K ﹤0.01% 454
2025
Q3 		$53.7K Hold
40,994
– – ﹤0.01% 448
2025
Q2 		$29.4K Hold
40,994
– – ﹤0.01% 412
2025
Q1 		$60.3K Sell
40,994
-1,681
-4% -$4K ﹤0.01% 363
2024
Q4 		$189K Hold
42,675
– – 0.01% 372
2024
Q3 		$176K Hold
42,675
– – ﹤0.01% 354
2024
Q2 		$278K Buy
42,675
+4,916
+13% +$34.8K 0.01% 277
2024
Q1 		$329K Sell
37,759
-1,381
-4% -$16.8K 0.01% 262
2023
Q4 		$448K Sell
39,140
-911
-2% -$9.01K 0.01% 228
2023
Q3 		$386K Hold
40,051
– – 0.01% 222
2023
Q2 		$426K Hold
40,051
– – 0.02% 218
2023
Q1 		$421K Sell
40,051
-7,795
-16% -$87.3K 0.02% 214
2022
Q4 		$593K Hold
47,846
– – 0.03% 189
2022
Q3 		$496K Buy
47,846
+1,155
+2% +$13.1K 0.03% 183
2022
Q2 		$538K Sell
46,691
-6,125
-12% -$72.2K 0.03% 186
2022
Q1 		$664K Buy
52,816
+4,684
+10% +$53.7K 0.03% 182
2021
Q4 		$561K Buy
48,132
+12
+0% +$147 0.03% 192
2021
Q3 		$628K Buy
48,120
+2,922
+6% +$37.8K 0.03% 187
2021
Q2 		$582K Buy
45,198
+4,697
+12% +$53.8K 0.03% 189
2021
Q1 		$453K Buy
40,501
+26,494
+189% +$280K 0.02% 196
2020
Q4 		$160K Hold
14,007
– – 0.01% 257
2020
Q3 		$126K Buy
14,007
+2,622
+23% +$26.1K 0.01% 239
2020
Q2 		$117K Sell
11,385
-5,715
-33% -$58.5K 0.01% 237
2020
Q1 		$173K Hold
17,100
– – 0.02% 212
2019
Q4 		$228K Hold
17,100
– – 0.01% 240
2019
Q3 		$147K Buy
+17,100
New +$166K 0.01% 249

Other funds holding IRWD

WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
RFG
Range Financial Group Tigard, Oregon $366M AUM 76.17% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Grimes & Company's IRWD Position: Q2 2026 in Review

Grimes & Company increased its Ironwood Pharmaceuticals (IRWD) stake by 34% in Q2 2026, buying an estimated $34.4K and bringing the position to 34,806 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #441.

Grimes & Company first reported a position in IRWD in Q3 2019 and has held it in 28 quarters since. The position peaked at $664K in Q1 2022. 14 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Grimes & Company held 34,806 shares of Ironwood Pharmaceuticals worth $147K as of Q2 2026.
  • Grimes & Company bought 8,919 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $34.4K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Grimes & Company's portfolio in Q2 2026, its #441 holding.
  • Grimes & Company first reported a position in Ironwood Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • Grimes & Company's Ironwood Pharmaceuticals position peaked at $664K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.